T. Rowe Price Investment Management
VRTX icon

T. Rowe Price Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-297
Closed -$133K – 931
2025
Q2 		$133K Buy
+297
New +$137K ﹤0.01% 661

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Investment Management's VRTX Position: Q3 2025 in Review

T. Rowe Price Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 297 shares — an estimated $133K sold.

T. Rowe Price Investment Management first reported a position in VRTX in Q2 2025 and held it in 1 quarter. The position peaked at $133K in Q2 2025. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • T. Rowe Price Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 297 Vertex Pharmaceuticals shares in Q3 2025, an estimated $133K.
  • T. Rowe Price Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • T. Rowe Price Investment Management's Vertex Pharmaceuticals position peaked at $133K in Q2 2025.
  • 1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.